KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Working Capital Changes (2018 - 2025)

Adaptive Biotechnologies' Other Working Capital Changes history spans 8 years, with the latest figure at -$799000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 16.77% year-over-year to -$799000.0; the TTM value through Dec 2025 reached $1.7 million, up 97.38%, while the annual FY2025 figure was $1.7 million, 2187.95% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$799000.0 at Adaptive Biotechnologies, down from $2.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $4.3 million in Q3 2023 and bottomed at -$46.5 million in Q3 2021.
  • The 5-year median for Other Working Capital Changes is $34476.0 (2021), against an average of -$5.5 million.
  • The largest YoY upside for Other Working Capital Changes was 36673.6% in 2022 against a maximum downside of 908.4% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$11.4 million in 2021, then dropped by 9.63% to -$12.5 million in 2022, then soared by 68.82% to -$3.9 million in 2023, then surged by 75.33% to -$960000.0 in 2024, then grew by 16.77% to -$799000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Other Working Capital Changes are -$799000.0 (Q4 2025), $2.5 million (Q3 2025), and $497000.0 (Q2 2025).